Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].

Pernod G, Elias A, Gouin I, Gaillard C, Nguyen P, Ouvry P, SiƩ P.

J Mal Vasc. 2012 Dec;37(6):300-10. doi: 10.1016/j.jmv.2012.09.003. Epub 2012 Nov 2. French.

PMID:
23122646
2.
3.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators., Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.

4.

The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

Cohen AT, Dobromirski M.

Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. Review.

PMID:
22371186
5.

Rivaroxaban for the treatment of pulmonary embolism.

Vanassche T, Verhamme P.

Adv Ther. 2013 Jun;30(6):589-606. doi: 10.1007/s12325-013-0041-4. Epub 2013 Jun 27. Review.

6.

Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).

Romualdi E, Donadini MP, Ageno W.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):841-4. doi: 10.1586/erc.11.62.

PMID:
21809964
7.

Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE.

Kline JA, Yealy DM.

Nat Rev Cardiol. 2012 May 8;9(7):378-80. doi: 10.1038/nrcardio.2012.65. No abstract available.

PMID:
22566060
8.

Rivaroxaban for treatment of venous thromboembolism in older adults.

Mitchell AP, Conway SE.

Consult Pharm. 2014 Sep;29(9):627-30. doi: 10.4140/TCP.n.2014.627. Review.

PMID:
25203412
9.

Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

Turpie AG, Kreutz R, Llau J, Norrving B, Haas S.

Thromb Haemost. 2012 Nov;108(5):876-86. doi: 10.1160/TH12-03-0209. Epub 2012 Sep 26. Review.

PMID:
23014816
10.

[Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].

Einecke D.

MMW Fortschr Med. 2012 Apr 19;154(7):24. German. No abstract available.

PMID:
22558862
11.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators..

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

12.

Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators..

Circulation. 2007 Jul 10;116(2):180-7. Epub 2007 Jun 18.

13.

Rivaroxaban, an oral direct factor Xa inhibitor.

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM.

Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . Review.

PMID:
18491993
14.

A cost-analysis model for anticoagulant treatment in the hospital setting.

Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

J Med Econ. 2014 Jul;17(7):492-8. doi: 10.3111/13696998.2014.914032. Epub 2014 Apr 30.

PMID:
24773068
15.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group..

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

16.

Oral rivaroxaban for symptomatic venous thromboembolism.

Landman GW, Gans RO.

N Engl J Med. 2011 Mar 24;364(12):1178; author reply 1178. doi: 10.1056/NEJMc1100734#SA1. No abstract available.

PMID:
21428778
17.

Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.

van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW.

Curr Med Res Opin. 2014 May;30(5):829-37. doi: 10.1185/03007995.2013.879439. Epub 2014 Jan 22.

PMID:
24432872
18.

Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.

Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH.

J Med Econ. 2014 Oct;17(10):691-5. doi: 10.3111/13696998.2014.946993. Epub 2014 Aug 4.

PMID:
25065536
19.

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

Loke YK, Kwok CS.

J Clin Pharm Ther. 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x. Review.

PMID:
21198726
20.

Rivaroxaban for thromboprophylaxis.

Lotke PA.

N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. No abstract available.

PMID:
19009675

Supplemental Content

Support Center